ArticleThe oncologist2026
Patients' and healthcare providers' views regarding dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: a qualitative study.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDose reduction of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) can reduce side effects and improve quality of life while maintaining treatment effectiveness and reducing costs.
objectiveThis study evaluates the views of both patients with CML and healthcare providers involved in CML care on dose reduction of TKIs.
methodsA qualitative study with semi-structured interviews via phone or video call was conducted with Dutch adult patients with CML and their healthcare providers. The COM-B model served as a theoretical framework to guide data collection and analysis to understand participants' capability, opportunity, and motivation for dose reduction. An inductive coding approach was utilized to derive themes from the data.
resultsEighteen patients and twelve healthcare providers (haematologists, nurse specialists, and pharmacists) participated, who in general were supportive of dose reduction. Two main themes were identified: (1) willingness and acceptance of dose reduction, which was shaped by participants' beliefs about the use of TKIs, the impact of TKIs on patients' quality of life, and associated hopes, fears and concerns; and (2) needs and preferences regarding dose reduction such as timing, eligibility, practical aspects, and shared-decision making.
conclusionPatients and healthcare providers have positive views on TKI dose reduction to improve the burden of CML treatment. Acceptance is shaped by their beliefs and concerns, while successful implementation depends on addressing practical needs and shared-decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.